secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001437749-23-014572
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Q1 net loss $6.6M; cash to fund ops through Q3 2023; Phase 3 topline data mid-2023
--------------------------------------------------------------------------------

- Net loss of $6.6M ($0.30/shr) vs $7.4M ($0.40) in Q1 2022; cash $11.3M at Mar 31, 2023, down from $18.5M.
- Cash sufficient to fund current plans through Q3 2023; additional financing needed for Phase 2a studies.
- Over 60% of ~400 patients enrolled in Phase 3 RECOVER trial for brilaroxazine in schizophrenia; topline data expected mid-2023.
- Brilaroxazine lipogel showed proof-of-concept in psoriatic mouse model; IND for psoriasis expected in 2024.
- May initiate Phase 2a studies in bipolar, MDD, and ADHD in H2 2023 subject to additional financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923014572/0001437749-23-014572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923014572/rvph20230512_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-014572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer